Hizentra (IgSC 20%) is a 20% IgG solution administered subcutaneously that is widely used in children and adults with primary immunodeficiency diseases (PIDD). There is limited data available regarding safety and efficacy of Hizentra 20% at faster flow rates within these patients.
This is a retrospective chart review, and quantitative data analysis, of patients with PIDD receiving scheduled Hizentra over the course of three years. Parameters including patient age, diagnosis, Hizentra dose, flow rate, volume/site, infusion time, number of infusion sites, IgG level and adverse reactions were evaluated to determine the efficacy and safety profile of corresponding Hizentra flow rates.
Fifty patients aged 3-82 years (mean 28.4 years) infused Hizentra via F900, F1200 or F2400 infusion rate tubing, 26 gauge needle, and Freedom 60 infusion pump. Mean dose was 39 ml/week. Average infusion time was 45 minutes (range 21- 84 min) with an average of 2 infusion sites (range 1-4), and average total flow rate of 50 ml/hr. Average flow rate per site was 21 ml/hr/site with average volume/site of 15 ml/site. Resulting IgG levels were between 413-1830 mg/dL. Minimal adverse reactions were reported including localized erythema and swelling.
This study demonstrates that Hizentra infused at faster flow rates and decreased infusion times is efficacious and well tolerated in patients with PIDD. PIDD patients treated with SCIG should continue to have their treatment regimen, including infusion parameters, individualized to achieve optimal outcomes. Further studies are indicated to determine the sustainability of these results.